SUTRO BIOPHARMA, INC. - 10-Q Filing

Sutro Biopharma reports Q3 2025 financial results highlighting ongoing R&D investment and collaboration activities with Astellas, Ipsen, and Vaxcyte.

SEC EDGAR ·

Tickers: $STRO

Read the full article at SEC EDGAR

More Regulatory news